| Date | Title | Description |
| 07.02.2025 | ExpreS2ion Biotech: Navigating Challenges and Seizing Opportunities in 2024 | ExpreS2ion Biotech Holding AB stands at a crossroads. The company recently unveiled its financial results for the fourth quarter and full year of 2024. Like a ship weathering a storm, ExpreS2ion has faced challenges but also found new winds... |
| 06.02.2025 | ExpreS2ion announces financial results for the fourth quarter of 2024 | ExpreS2ion announces financial results for the fourth quarter of 2024
Thu, Feb 06, 2025 08:30 CET Report this content
Hørsholm, Denmark, 6 February 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and f... |
| 31.01.2025 | Evaxion announces closing of $10.8 million public offering | COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an aggr... |
| 31.01.2025 | Evaxion announces closing of $10.8 million public offering | COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an aggr... |
| 30.01.2025 | Evaxion announces pricing of $10.8 million public offering | COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggr... |
| 30.01.2025 | Evaxion announces pricing of $10.8 million public offering | COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggr... |
| 15.11.2024 | ExpreS2ion and Evaxion: A New Dawn for CMV Vaccines | In the world of biotechnology, breakthroughs often feel like whispers in a storm. Yet, the recent collaboration between ExpreS2ion Biotech and Evaxion Biotech is a thunderclap. Their joint effort focuses on a vaccine for cytomegalovirus (CM... |
| 12.11.2024 | ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002 | ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002
Tue, Nov 12, 2024 14:00 CET Report this content
Hørsholm, Denmark, 12 November 2024 – ExpreS2ion Biotech Holding AB’s affiliate Ex... |
| 05.06.2023 | Evaxion’s AI Technology Identifies Cancer Vaccine Targets Associated With Longer Progression-free Survival Of Melanoma Patients In The EVX-01 Phase 1 Clinical Trial | The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability
Positive clinical responses were reported in 8 out of 12 EVX-01 treated patients
High-quality neoantigens, predicted by AI tec... |
| 15.04.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 15th April 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 14.04.2023 | Evaxion And Pennsylvania State University Publish Preclinical Data Validating Our AI-based Viral Vaccine Discovery Platform | Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful publication in Frontiers of Immunology of preclinical data demonstrating the effectiveness of its proprietary A... |
| 23.03.2023 | Evaxion Presents A New Source Of AI-derived Immunotherapeutic Targets Strongly Associated With The Overall Survival Of Cancer Patients | Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy
This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy
Evaxion Biotech A/S , a clinical-st... |
| 30.06.2022 | Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target | COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced tha... |
| 23.06.2022 | Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer | COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced tha... |
| 07.06.2022 | Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital | COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today th... |
| 10.11.2021 | Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares | COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives... |
| 09.11.2021 | Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares | COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives... |
| 09.11.2021 | Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update - Form 6-K | Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update
● Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depository Shares (ADSs) for gross proceeds of $27.6... |
| 09.11.2021 | Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update | Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) for gross proceeds of $27.6 million before deducting underwriter fees and commissions and other offering expen... |
| 05.11.2021 | Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering | COPENHAGEN, Denmark, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives... |
| 05.11.2021 | Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering | COPENHAGEN, Denmark, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives... |
| 05.11.2021 | Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering - Form 6-K | Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
Copenhagen, Denmark, November 5, 2021 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company... |
| 25.10.2021 | Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma | COPENHAGEN, Denmark, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and ... |
| 14.10.2021 | Evaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership Award | Recognizes achievements in AI-enabled drug discovery
Highlights how Evaxion’s platforms help to design novel immunotherapies efficiently
COPENHAGEN, Denmark, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or... |
| 12.10.2021 | Evaxion Biotech to Present Work on AI-Immunology Core Technology at Immuno UK 2021 | COPENHAGEN, Denmark, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives... |
| 12.08.2021 | Evaxion Biotech A/S : Announces Q2 2021 Financial Results and Provides Business Update (Form 6-K) | Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update
● Data reported in early July from EVX-01 clinical program showed a robust anti-tumor effect in combination with anti-PD-1 treatment for patients with metastat... |
| 12.08.2021 | Evaxion Biotech A/S : Announces Q2 2021 Financial Results and Provides Business Update | Data reported in early July from EVX-01 clinical program showed a robust anti-tumor effect in combination with anti-PD-1 treatment for patients with metastatic melanoma, supporting advancement into a Phase 2b clinical trial Data also report... |
| 13.05.2021 | EVAXION BIOTECH A/S
Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update | Raised net proceeds of $27.9 million in U.S. initial public offering in February 2021
Lead programs EVX-01 and EVX-02 on track for Phase 1/2a data readouts late in Q2
Product candidates EVX-03 and EVX-B1 progressing through pre-clinical dev... |
| 06.04.2021 | EVAXION BIOTECH A/S
Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update | Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 millionClinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02Cash reserv... |
| 16.03.2021 | Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports | COPENHAGEN, Denmark, March 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and... |
| 16.02.2021 | Evaxion Biotech Opens New Office and Laboratories to Support Future Growth | COPENHAGEN, Denmark, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and ... |